drugset / Trial / NCT07294664
PD1/TGFβ In Combination With SHR2554 or Apatinib And Chemotherapy For First - Line Treatment Of Gastric Cancer
Non-randomizedParallel-groupOpen-labelTreatment
Summary
Immunotherapy combined with chemotherapy has become the standard first-line treatment regimen for gastric cancer. However, a subset of patients still fail to benefit or derive only limited benefit from this approach. This study aims to evaluate the addition of immunomodulatory EZH2 inhibitors or anti-angiogenic agents to the baseline regimen of immunotherapy combined with chemotherapy, in order to further improve patient treatment benefits.
Timeline
- Start
- 2025-06-15
- Primary completion
- 2027-07-15
- Completion
- 2028-07-15
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Capecitabine | Small molecule | 1000 mg/kg | — |
| Subject | Oxaliplatin | Small molecule | 130 mg/m2 | — |
| Subject | Retlirafusp alfa | Protein / enzyme biologic | 1800 mg | — |
| Subject | Rivoceranib | Small molecule | 250 mg | — |
| Subject | SHR2554 | Small molecule | 350 mg | — |